BCR and neoplasm: The BCR–ABL1 kinase drives multiple signaling pathways, including cell growth, survival, invasion and angiogenesis and tumor initiation and progression, indicating poor prognosis in CML patients and acute lymphoblastic leukemia (ALL) patients [4].